TNK is the shorthand name for tenecteplase, a clot-dissolving medication used to treat ischemic stroke. It works by breaking apart the blood clot blocking an artery in the brain, restoring blood flow before permanent damage sets in. As of 2026, the American Heart Association and American Stroke Association recommend tenecteplase as a first-line option alongside the older drug alteplase for patients who can be treated within 4.5 hours of symptom onset.
How TNK Dissolves a Stroke-Causing Clot
An ischemic stroke happens when a blood clot lodges in an artery supplying the brain. TNK targets the fibrin mesh that holds the clot together. Once it binds to that fibrin, it activates a natural enzyme called plasmin, which breaks the clot apart from the inside. As the clot dissolves, blood flow returns to the oxygen-starved brain tissue. This process is called thrombolysis, and the entire class of drugs that do this are often called “clot busters.”
TNK is a bioengineered variant of alteplase (the clot buster hospitals have used for decades). The engineering gives it two practical advantages: it binds more tightly to fibrin, meaning it concentrates its activity on the clot rather than affecting clotting proteins elsewhere in the body, and it lasts longer in the bloodstream, which changes how it can be given.
Why TNK Is Replacing Alteplase
The biggest practical difference is how the drug is delivered. Alteplase requires a small initial injection followed by a one-hour continuous IV drip. TNK is a single injection that takes seconds. In a stroke emergency, that simplicity matters. It means faster treatment in the emergency department, easier use in ambulances or smaller hospitals, and fewer steps where something can go wrong.
Clinical outcomes are comparable. In the ORIGINAL trial, which enrolled nearly 1,500 patients, 72.7% of those who received TNK achieved excellent functional recovery at 90 days, compared with 70.3% of those who received alteplase. Those numbers are close enough that the trial confirmed TNK is not inferior to the older drug.
Where TNK may have a real edge is safety. A large collaborative analysis of over 9,000 patients found that symptomatic bleeding inside the brain, the most feared complication of any clot-busting drug, occurred in 1.8% of TNK patients versus 3.6% of alteplase patients. That’s roughly half the rate. While no clot buster is risk-free, a lower bleeding rate is a meaningful advantage.
Who Can Receive TNK and When
The standard treatment window is within 4.5 hours of when symptoms started or were last known to be absent. This is the same window that has applied to alteplase for years. The dose is weight-based: 0.25 mg per kilogram of body weight, with a maximum of 25 mg. In practice, a person weighing under 60 kg receives 15 mg, while someone 90 kg or above receives the full 25 mg cap.
Not everyone with stroke symptoms is eligible. The medication is only for ischemic strokes (caused by a clot), not hemorrhagic strokes (caused by bleeding). Before giving TNK, the medical team performs a CT scan to rule out bleeding and confirms that the timing falls within the treatment window. Certain conditions, like very high blood pressure that can’t be brought under control or recent major surgery, can also disqualify someone.
TNK for Large Vessel Occlusions
Some ischemic strokes are caused by a clot in one of the brain’s major arteries. These large vessel occlusions tend to cause more severe strokes and often require a mechanical procedure called thrombectomy, where a catheter is threaded into the artery to physically pull the clot out. TNK can be given before thrombectomy to start dissolving the clot while the surgical team prepares.
A meta-analysis of over 1,100 patients with large vessel occlusions found that TNK produced significantly higher rates of reopening the blocked artery compared to no clot-busting drug. About 33.9% of TNK-treated patients achieved excellent functional outcomes at 90 days, compared with 27.4% in control groups. The benefit was especially clear in patients who did not go on to receive thrombectomy, suggesting TNK alone can sometimes resolve even large clots.
TNK Beyond the 4.5-Hour Window
Researchers are actively studying whether TNK can help patients who arrive later than 4.5 hours after symptom onset. Many stroke patients don’t get to a hospital within that standard window, whether because they were asleep when the stroke began, didn’t recognize the symptoms, or had trouble reaching care. A systematic review of trials testing TNK in the 4.5 to 24-hour range found that it appeared safe and effective for carefully selected patients, improving functional outcomes without a significant increase in bleeding.
Selection in this extended window depends heavily on brain imaging. Advanced scans can identify patients who still have salvageable brain tissue despite the delay, meaning there is a mismatch between the area already damaged and the larger area at risk. When imaging shows this mismatch, treatment can still make a difference even many hours after symptoms began.
What to Expect During Treatment
If you or a family member receives TNK for a stroke, the experience is straightforward from the patient’s perspective. After the CT scan confirms an ischemic stroke, a nurse or physician delivers a single injection, typically into a vein in the arm. The whole administration takes only a few seconds. Afterward, the medical team monitors closely for several hours, watching for signs of improvement and any complications, particularly bleeding.
Most patients stay in an intensive care or stroke unit for at least 24 hours after receiving any clot-busting drug. During that time, blood pressure is tightly controlled and a follow-up brain scan is performed to check for bleeding. The 90-day recovery data from clinical trials gives a realistic picture of what’s possible: roughly 7 out of 10 patients treated within the standard window achieve little to no disability. Outcomes are better the earlier the drug is given, which is why stroke teams emphasize speed at every step.